Skip to main content
. 2021 Jan 28;11:609490. doi: 10.3389/fimmu.2020.609490

Table 2.

In vitro characteristics of NTRC 3883-0 and epacadostat.

Assay NTRC 3883-0 epacadostat
hIDO1 123 (116–130) (n = 85) 27 (25–29) (n = 91)
hTDO < 20% inhibition @ 31,600 (n = 82) 54 (50–58) (n = 89)
HEK-hIDO1 119 (n = 2) 7.9 (n = 2)
HEK-hTDO < 20% inhibition @ 31,600 (n = 2) 24,100 (n = 2)
A375 + IFNγ (hIDO1) 182 (155–214) (n = 63) 20 (18–22) (n = 70)
SW48 (hTDO) < 20% inhibition @ 31,600 (n = 19) 6,460 (5,650–7,390) (n = 24)
hWB + IFNγ (hIDO1) 378 (349–408) (n = 12) 54 (48–62) (n = 12)
mIDO1 93 (n = 2) 39 (30–49) (n = 4)
mTDO < 20% inhibition @ 31,600 (n = 2) 225 (102–492) (n = 3)
B16F10-mIDO1 18 (n = 2) 88 (n = 2)
GL-261-mTDO < 20% inhibition @ 31,600 (n = 2) 28% inhibition @ 31,600 (n = 2)

Potency (IC50) in nM of IDO1 inhibitors NTRC 3883-0 and epacadostat in biochemical and cell-based assays for human (h) and mouse (m) IDO1 or TDO. 95% confidence intervals and number of experimental replicates (n) are given within brackets. hWB, human whole blood.